Drug profile · INN
ledipasvir
HARVONI
ledipasvir (HARVONI) is a nonstructural protein 5a inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — ledipasvir
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
ledipasvir (HARVONI) is a nonstructural protein 5a inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Nonstructural protein 5A inhibitor
Primary target: Nonstructural protein 5A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ledipasvir?
ledipasvir (HARVONI) is a nonstructural protein 5a inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ledipasvir?
HARVONI is a marketed brand name for ledipasvir. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ledipasvir?
ledipasvir has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.